FTSE 100 today: Index rises, GBP flat; Mitchells & Butlers jumps, Whitbread falls
Director Arthur F. Golden recently purchased 9868 shares of Turn Therapeutics Inc. NASDAQ:TTRX common stock at prices ranging from $3.25 to $3.50, inclusive, in a transaction dated November 24, 2025. The total value of the purchase amounted to $33945.The insider buy comes as TTRX shares have gained 16.61% over the past week, though the stock remains down nearly 53% over the past six months. With a current market capitalization of $103 million and trading at $3.30, InvestingPro analysis suggests the stock is overvalued against its Fair Value. The company’s financial health is rated as "WEAK" with negative earnings per share of -$0.14.Following the transaction, Golden directly owns 60602 shares of the company, some of which are restricted stock units granted under the Issuer’s 2025 Omnibus Incentive Plan. InvestingPro identifies 8 additional investment tips for TTRX, including insights on profitability and valuation metrics.
In other recent news, Turn Therapeutics announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this newly created role, Scott will manage investor relations, capital markets strategy, and corporate communications, while also supporting licensing and partnership initiatives. Additionally, Turn Therapeutics has entered into a global supply, development, and license agreement with Medline. This collaboration aims to develop, manufacture, and commercialize products using Turn’s PermaFusion delivery platform. Medline is recognized as the largest provider of medical-surgical products and supply chain solutions in the healthcare sector. Furthermore, Turn Therapeutics has appointed Arthur Golden to its Board of Directors. Golden brings over 40 years of experience in corporate law, governance, and strategic advisory work. He has extensive experience, having served as Senior Counsel at Davis Polk & Wardwell LLP and as a Director at Emerson Electric.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.